Bio-Techne Corporation
Bio-Techne Reports Second Quarter Fiscal 2024 Results and Announces Cash Dividend
Summary
Bio-Techne Corporation reported its financial results for the second quarter of fiscal 2024, showing a decline in organic revenue by 2% and GAAP earnings per share of $0.17. The company also announced a cash dividend and highlighted increased cash flow from operations. Despite challenges in the BioPharma sector, Bio-Techne saw growth in its instrument consumables and maintained a strong financial position with $142.5 million in cash flow from operations.
Profitelligence Alerts
Get alerts for TECH
Be first to know when Bio-Techne Corporation files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Bio-Techne Corporation
Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.
Official SEC Documents
Advertisement